Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 100
Avg Vol 6,708
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 66%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9093 3855
Address:
55 Flemington Road, Level 4, North Melbourne, Australia
Latest News on TLPPF
No data available.